A Phase 1 interventional study of WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS in Parkinson Disease, sponsored by Hong Kong WD Pharmaceutical Co., Limited. Status unknown at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-10.
Sponsored by Hong Kong WD Pharmaceutical Co., Limited · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing levodopa in Parkinson Disease — 3 open to participants now, 3 under way, none of them phase 3. Levodopa · Parkinson Disease.
Among the 51 studies testing levodopa in Parkinson Disease, this one is the 48th largest by planned enrollment of the 50 interventional ones that give a count, is the only one that started in 2020, is one of 8 in phase 1, and was the 46th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →3 of the 51 studies testing levodopa in Parkinson Disease are open now, in 2 countries. Recruiting first, the newest first:
Second Affiliated Hospital of Soochow University · Sites in China
Ages 30–80
Emory University · Sites in United States
Ages 45–75 · Healthy volunteers
Beth Israel Deaconess Medical Center · Sites in United States
By country, each count listing its studies:
Levodopa: first FDA approval 1970 (LARODOPA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 11 · Phase 3 12 · Phase 4 17
First in 1998; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 56 across the 50 interventional studies. Of the 45 that completed or were terminated, 18 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 51 have an industry lead sponsor. The 10 most frequent:
Hong Kong WD Pharmaceutical Co., Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.
Hong Kong WD Pharmaceutical Co., Limited has 3 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
1 of the studies testing levodopa in Parkinson Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06234995Emory UniversityCortical Electrophysiology of Response Inhibition in Parkinson's Disease | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies testing levodopa in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Phase 1 PK study is planned to evaluate the food effect on WD-1603 pharmacokinetics
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
a. Surgically sterilized at least 6 months prior to study participation or If of child bearing potential is willing to use a suitable and effective double barrier method or intra uterine device during the study.
And b. Serum Pregnancy test must be negative.
Exclusion Criteria:
Receipt of an medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication**.
** If investigational medicinal product is received within 90 days where there is no blood loss except safety lab testing, subject can be included considering 10 half-lives duration of investigational medicinal product received.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A will be given under fed conditions by intra-oral single dose administration
Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
Treatment B will be given intra-orally and orally under fed conditions by single dose administration
Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
Treatment C will be given orally under fed conditions by single dose administration
Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
Treatment D will be given orally under fasting conditions by single dose administration
Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
Drug pages: WD-1603Studies of WD-1603WD-1603 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LevodopaStudies of LevodopaLevodopa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
Cmax
Pharmacokinetics Measurements to Determine Cmax for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations
Time frame: Day 1 and Day 2
AUC0-t
Pharmacokinetics Measurements to Determine AUC0-t for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations
Time frame: Day 1 and Day 2
AUC0-∞
Pharmacokinetics Measurements to Determine AUC0-∞ for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations
Time frame: Day 1 and Day 2
Tmax
Pharmacokinetics Measurements to Determine Tmax for Carbidopa (CD) and
Time frame: Day 1 and Day 2
t1/2
Pharmacokinetics Measurements to Determine t1/2 for Carbidopa (CD) and
Time frame: Day 1 and Day 2
Started Aug 2020 (actual). Primary completion is estimated for Sep 2020, 0 months after the start.
Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 0 months is below that.
Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: WD-1603 · Levodopa
Hong Kong WD Pharmaceutical Co., Limited